Abstract
by hyperemia and mucosal thickness and weight lose. On day 3 after colitis induction, 66% and 16% of Desnosumab-DSS-treated mice had weight loss and mucosal thickening respectively, compared to 100% and 66% of vehicle DSS-treated mice (p<0.05). Composite macroscopic score was 41% lower in Desnosumab-DSS-treated mice than in vehicle DSStreated mice (p<0.05). All four markers including diarrhea, hyperemia, thickness and adhesion were decreased. Denosumab treatment decreased the colonic MPO activity (p<0.05). Colonic IL-1b levels decreased from 41.1±1.7 in vehicle-DSS-treated mice to 13.11±1.3 pg/ mg of tissue in Denosumab-DSS-treated mice (p<0.05). Conversely, no effect was evident on colonic IL-6 levels. In control mice (without colitis) Denosumab did not affect any inflammatory marker. Conclusions: These results support the hypothesis that preventative treatment with Denosumab modulates intestinal inflammation in a murine model of colitis. This provides a rationale for considering Denosumab as a therapy in CD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
